Faecal tumour M2 pyruvate kinase: a new, sensitive screening tool for colorectal cancer by Hardt, P D et al.
Faecal tumour M2 pyruvate kinase: a new, sensitive screening tool
for colorectal cancer





2,{ and HU Kloer
1
1Third Medical Department and Policlinic, Giessen University Hospital, Justus-Liebig-University of Giessen, Rodthohl 6, Giessen 35392, Germany;
2Institute
of Biochemistry and Endocrinology, Veterinary Faculty, University of Giessen, Frankfurter Strasse 100, Giessen 35392, Germany;
3Medical Department
and Surgical Department of the Asklepios Clinic, Goethestrasse 4, Lich 35423, Germany
Proliferating cells, especially tumour cells, express a special isoenzyme of pyruvate kinase, termed M2-PK, which can occur in a
tetrameric form with a high affinity to its substrate, phosphoenolpyruvate (PEP), and in a dimeric form with a low PEP affinity. In
tumour cells, the dimeric form is usually predominant and is therefore termed Tumour M2-PK. The levels of Tumour M2-PK within
tumours and in EDTA-plasma correlate with staging and the ability of the tumour cells to metastasise. Since most colorectal tumours
grow intraluminally, it appeared interesting to determine whether Tumour M2-PK is detectable in the faeces of tumour patients. Stool
samples were tested by ELISA from controls without colorectal cancer and colorectal cancer patients. Whereas Tumour M2-PK
levels were low in the control group (mean value7s.e.m.: 3.370.4, n¼144), they were high in the case of colorectal cancer
(56.1715.3, n¼60). At a cutoff value of 4Uml
 1, the sensitivity was 73%. TNM and Dukes’ classification of the tumours revealed a
strong correlation between faecal Tumour M2-PK levels and staging. The determination of Tumour M2-PK in faeces provides a new
promising screening tool for colorectal tumours.
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One alteration consistently found during tumour formation,
including gastrointestinal tumours, is the upregulation of glyco-
lytic enzymes. This upregulation takes place at the RNA and
protein level, as well as at the level of enzymatic activities (Durany
et al, 1997; Eigenbrodt et al, 1997; Mazurek et al, 2000; Hegde et al,
2001; Atsumi et al, 2002; Birkenkamp-Demtroder et al, 2002;
Williams et al, 2003). In addition, in the case of the glycolytic
enzyme pyruvate kinase, a loss of the tissue-specific isoenzymes
(L-PK in the liver, M1-PK in muscle and brain and R-PK in
erythrocytes) and expression of the pyruvate kinase isoenzyme
type M2 (M2-PK) is described in all tumours investigated thus far
(Figure 1A) (Staal and Rijksen, 1991; Mazurek et al, 1997;
Steinberg et al, 1999). The increase in M2-PK levels has been
recorded by the determination of enzymatic activities, cellulose
acetate electrophoresis, Western blotting and immunohistology
(Reinacher and Eigenbrodt, 1981; Staal and Rijksen, 1991;
Eigenbrodt et al, 1992; Mazurek et al, 2000). In healthy tissues,
all isoenzymes of pyruvate kinase consist of four subunits whereby
hybrids of the different forms can also occur (Saheki et al, 1978,
1979). Whereas in the epithelium of the upper gastrointestinal
tract (oesophagus and stomach) hybrids between M1 and M2 have
been found, the lower gastrointestinal tract (jejunum, colon and
rectum) is characterised by hybrids of L and M2-PK (Saheki et al,
1978, 1979). In gastrointestinal tumours, only subunits of the type
M2 are detectable and pyruvate kinase is mainly in the dimeric
form (Mazurek et al, 2000). Therefore, the dimeric form of M2-PK
has been termed Tumour M2-PK. The tetramer:dimer ratio of M2-
PK can be quantified by gel permeation, isoelectric focusing or by
ELISA (Cerwenka et al, 1999; Schulze, 2000; Mazurek et al, 1997,
2001; Mazurek and Eigenbrodt, 2003). The upregulation of the M2-
PK protein is under the control of HIF-1 and ras, which are both
consistently altered in gastrointestinal tumours (Kress et al, 1998;
Mazurek et al, 2001; Nishikawa et al, 2002; Mazurek and
Eigenbrodt, 2003). The tetramer:dimer ratio of M2-PK is under
the control of several oncoproteins, such as pp60
v src kinase, HPV-
16 E7 and A-Raf (Figure 1B) (Eigenbrodt et al, 1998b; Zwerschke
et al, 1999; Le Mellay et al, 2002). Interestingly, pp60
c src kinase
and A-Raf are consistently altered in gastrointestinal tumours
(Bolen et al, 1987; Iravani et al, 1998; Irby et al, 1999; Luckett et al,
2000; Dehm et al, 2001; Dhillon et al, 2003).
Determinations of Tumour M2-PK in EDTA-plasma samples of
patients with gastrointestinal tumours revealed an upregulation of
Tumour M2-PK in oesophageal, gastric, colonic and rectal
carcinomas (Hardt et al, 2000; Schulze, 2000; Schneider and
Schulze, 2003). Recently, we noticed that Tumour M2-PK can be
detected and quantified in the faeces of patients with gastro-
intestinal cancer (Hardt et al, 2003). The present study describes
the clinical utility of the determination of Tumour M2-PK in the
stool of patients with colorectal cancer and control subjects
without endoscopic evidence of colorectal neoplasms.
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After obtaining informed consent, patients given appointments for
colonoscopy for various reasons were asked to provide one stool
sample for measuring faecal Tumour M2-PK. A short standard
questionnaire about the patient’s history was used to record
clinical data. Stool samples of patients with colorectal cancer and
patients without pathological findings were tested.
Endoscopies were carried out as standard investigations.
Histology was obtained from the routine biopsies and/or from
surgery. All data were collected prospectively and recorded on
standardised forms. The study protocol was approved by the ethics
committee of Giessen University Hospital.
Measurement of faecal tumour M2-PK concentrations
Tumour M2-PK was measured with a commercially available
sandwich ELISA (ScheBo
s Biotech AG, Giessen, Germany). For
sample preparation, 100mg of the single, random stool specimen
was extracted in 10ml extraction buffer and diluted 1:10 in the
sample washing buffer provided. The ELISA plate is coated with a
monoclonal antibody against Tumour M2-PK. Tumour M2-PK
from stool samples or standards binds to the antibody. A second
monoclonal antibody, which is biotinylated, binds to Tumour M2-
PK during the next incubation. Both monoclonal antibodies
against Tumour M2-PK specifically react with Tumour M2-PK
(dimeric form of M2-PK) and do not crossreact with the other
isoforms of pyruvate kinase (type L, R, M1 and tetrameric M2-PK).
In the next incubation step, a conjugate of peroxidase (POD) and
streptavidin binds to the biotin moiety. POD oxidises the substrate
3,30,5,50-tetra-methyl benzidine (TMB) and the oxidised form of
TMB is determined photometrically at 450nm.
Statistical analysis
For the statistical comparison of the nonparametrically distributed
data, the Kruskall–Wallis ANOVA test was used (Statistica
Version 5.0, StatSoft
s Inc., Tulsa, USA).
Sensitivity was calculated as the number of patients with
colorectal cancer who tested positive for Tumour M2-PK (true
positives) divided by the total number of histologically confirmed
tumour patients (true positives plus false negatives), expressed as a
percentage (i.e. sensitivity¼(number of true positives/number of
tumour patients) 100).
Specificity was calculated as the number of controls who tested
negative for Tumour M2-PK (true negatives) divided by the total
number of control subjects (true negatives plus false positives),
expressed as a percentage (i.e. specificity¼(number of true
negatives/number of patients without pathological findings at
colonoscopy) 100).
RESULTS
In all, 60 patients with colorectal cancer have been evaluated to
date. A total of 144 patients underwent total colonoscopy without
any pathological findings and served as controls. The range of
faecal Tumour M2-PK levels is shown in Figure 2. There is a highly
significant difference between tumour patients and controls. At a
cutoff level of 4Uml
 1, the sensitivity was calculated to be 73%
and the specificity as 78%. TNM classification of the colorectal
tumours according to the criteria of the American Joint Committee
on Cancer (AJCC, 2002), as well as the Dukes’ classification,
revealed a strong correlation between the amount of faecal































Figure 1 (A) Pyruvate kinase isoenzyme equipment of different tissues.














































Controls, n = 144 Colorectal carcinomas, n = 60
Controls, n = 144 Colorectal carcinomas, n = 60
25% 
Figure 2 Tumour M2-PK levels in stool samples of patients with
colorectal cancer and healthy control individuals. Sensitivity: 73%; specificity:
78%.
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yincreased from 57 and 59% in the case of T1 and Dukes’ A,
respectively, to 78% in the case of T4 and 90% in the case of Dukes’
D.
The intra-assay variance was evaluated by 18-fold determination
of five samples (5–66Uml
 1), giving an average coefficient of
variance (CV) of 7.9% (3.5–13.6%). The interassay variance was
calculated with five samples between 4 and 73Uml
 1, tested on 10
different days. The average CV was 7.3% (3.8–12.6%).
DISCUSSION
In the present study, Tumour M2-PK was measured in the faeces of
patients with colonoscopy-proven cancer of the colon and rectum.
The data presented here are the results of the first extensive study
in this field, which was conducted in secondary-care gastrointest-
inal clinics and reflects the current presentation of colorectal
cancer in this setting.
The faecal levels of Tumour M2-PK are significantly higher in
patients with colorectal cancer than in the control group without
colorectal cancer (Figure 2). Overall sensitivity is 73% and
specificity is 78%. All patients in our study underwent complete
colonoscopy to confirm (together with histology) colorectal cancer
or exclude it. When similarly compared against colonoscopy,
screening with a guaiac-based faecal occult blood test (FOBT) had
a sensitivity of 24% in a recent study (Lieberman et al, 2001).
Nevertheless, large randomised studies of screening with FOBT
have demonstrated a reduction in mortality or risk of 15–33%
(Hardcastle et al, 1996; Mandel et al, 1999; Jorgensen et al, 2002).
Owing to the high sensitivity, the determination of Tumour M2-
PK in stool samples might be a valuable new screening tool for
colorectal cancer. Furthermore, a close correlation was found
between Tumour M2-PK levels and tumour staging for both TNM
and Dukes’ classification (Table 1; Figure 3).
An increase of Tumour M2-PK levels has also been measured in
EDTA-plasma samples of patients with colorectal cancer (Hardt
et al, 2000; Schulze, 2000; Schneider and Schulze, 2003). The
sensitivity of the Tumour M2-PK EDTA-plasma test was lower
(nonmetastasising cancer: 48%; metastasising cancer: 54%) than
the Tumour M2-PK stool test (Dukes’ A: 59%; Dukes’ D: 90%).
Furthermore, Tumour M2-PK levels are also increased in EDTA-
plasma samples from patients with solid tumours at various sites,
including renal, lung and breast cancers (Oremek et al, 1999;
Wechsel et al, 1999; Lu ¨ftner et al, 2000; Schneider et al, 2000;
Mazurek et al, 2002). Therefore, for the screening of colorectal
cancer the determination of faecal Tumour M2-PK is superior to
the EDTA-plasma test.
However, analogous to studies in breast, lung and kidney cancer
patients (Wechsel et al, 1999; Lu ¨ftner et al, 2000; Hoopmann et al,
2002; Schneider et al, 2002), a possible field of application for the
Tumour M2-PK EDTA-plasma test may be the monitoring and
follow-up of patients with colorectal cancer.
Immunohistological staining of Tumour M2-PK in various rat
and human tumours (breast, renal, lung, colon, rectal and skin
tumours) revealed that increased Tumour M2-PK in tumour cells
is a general metabolic alteration during tumorigenesis and
correlated with malignancies of the tumours (Reinacher and
Eigenbrodt, 1981; Bahnemann et al, 1990; Eigenbrodt et al, 1992;
Schneider et al, 2000).
The upregulation of the M2-PK isoenzyme can be caused by
mutations in the ras gene and upregulation of HIF-1 (Kress et al,
1998; Mazurek et al, 2001). HIF-1 is stabilised by p53 mutations
(Kress et al, 1998; Ravi et al, 2000). Indeed, mutations in the ras
oncogene and p53 antioncogene are detectable in 40–60% of
colorectal cancers (Bos, 1989; Kinzler and Vogelstein, 1996; Dong
et al, 2001; Rengucci et al, 2001; Nishikawa et al, 2002; Smith et al,
2002).
The determination of mutated oncogenes and antioncogenes in
stool samples has the advantage of high specificity. For example,
mutations of K-ras, p53 or within the adenomatous polyposis coli
(APC) gene were not detected in any stool samples of healthy
controls (Rengucci et al, 2001; Nishikawa et al, 2002; Traverso et al,
2002). However, due to the genetic heterogeneity within colorectal
cancer, a multitarget assay panel (e.g. mutations of k-ras, p53 and
APC genes, as well as Bat-26 (a microsatellite instability marker)
and highly amplifiable ‘long’ DNA) has to be screened to reach
high sensitivities (63–95%) (Ahlquist et al, 2000; Tagore et al,
2003).
Since M2-PK is a direct target of several oncoproteins, the
determination of faecal Tumour M2-PK might be more sensitive
than the detection of mutations in the oncoproteins and
antioncoproteins themselves.
In contrast to many other genes, no mutations have yet been
found in the M2-PK gene (http://www.pubmed.gov: nucleotide,
tumour pyruvate kinase type M2). Furthermore, the overexpres-
sion of a mutated M2-PK protein suppresses A-Raf transformation
in NIH 3T3 cells, which underlines the central role of M2-PK
within the tumour metabolome (Le Mellay et al, 2002). Indeed,
pyruvate kinase controls the exit of glycolysis and is responsible
for net ATP production of this pathway, especially under hypoxic














Controls 144 1.6 3,3 0.4 0.1–31
T1 7 5.5 11.1 5.9 1.3–45
T2 11 10.0 23.8 9.9 1.1–100
T3 33 34.2 55.5 13.7 1.0–380
T4 9 47.8 132.7 86.2 0.2–800
Dukes’ A 17 6.4 19.4 6.9 1.1–100
Dukes’ B 16 14.5 31.5 8.5 1.0–100
Dukes’ C 17 46.8 57.1 15.9 0.2–215
Dukes’ D 10 36.4 156.2 81.1 0.7–800
TNM classification according to AJCC, 2000: T1: tumour invades submucosa; T2:
tumour invades muscularis propria; T3: tumour invades through muscularis propria
into subserosa or into nonperitonealised pericolic or perirectal tissues; T4: tumour
directly invades other organs or structures and/or perforates visceral peritoneum.
Dukes’ staging according to Cuthbert Dukes, 1932: Dukes’ A: the cancer confines to
most superficial cell layers of colon and rectum; Dukes’ B: the cancer penetrates the
colon wall; Dukes’ C: the cancer spreads to the lymph nodes; Dukes’ D: the cancer










































































Figure 3 Correlation between faecal Tumour M2-PK levels and TNM
staging. Sensitivities: T1, 57%; T2, 64%; T3, 78%; and T4, 78% (see Table 1).
Faecal tumour M2-PK for colorectal cancer screening
PD Hardt et al
982





























yconditions. M2-PK can switch between a highly active tetrameric
form with a high affinity to its substrate, phosphoenolpyruvate
(PEP), and a nearly inactive dimeric form with a low PEP affinity
(Figure 1B). The tetramer:dimer ratio of M2-PK is regulated by
oncoproteins and metabolic intermediates, such as fructose 1,6-P2
and serine, and determines whether glucose carbons are converted
to pyruvate and lactate under the production of energy (tetrameric
form) or are channelled into synthetic processes, such as DNA,
phospholipid and amino-acid synthesis (dimeric form) (Mazurek
et al, 1997; Griffiths et al, 2002; Boren et al, 2003). When M2-PK is
mainly in the nearly inactive dimeric form (Tumour M2-PK)
energy is provided by the degradation of the amino-acid glutamine
to lactate, which has been termed glutaminolysis (Figure 1B)
(http://www.metabolic-database.com).
The oscillation between the highly active tetrameric form and
the nearly inactive dimeric form allows optimal adaptation of the
tumour metabolome to the varying nutrient and oxygen supply
constantly found in solid tumours (Eigenbrodt et al, 1998a; Vaupel
et al, 2003).
Tumour M2-PK is detected with an ELISA that can be easily
performed in every routine laboratory. Samples are stable and the
sensitivity of the Tumour M2-PK test is higher than the detection
of mutations in p53, ras or APC (Rengucci et al, 2001; Nishikawa
et al, 2002; Traverso et al, 2002). Therefore, the detection of
Tumour M2-PK levels in the stool might provide an interesting
screening tool for colorectal cancer. To further validate this new
test in a larger cohort, a larger cross-sectional study will be
performed in the future.
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